pharma · Ovarian Cancer · Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer · ANIX
Anixa Biosciences
Anixa Biosciences Inc
Anixa Biosciences is a pharma organization headquartered in San Jose, USA. It trades on NYSE under ticker ANIX. Primary therapeutic focus areas include Ovarian Cancer, Pathologic Stage IIA-IIIC Triple-Negative Breast Can
San Jose, USA HQ
1982 Founded
12 Employees
Public company Type
ANIX · NYSE Ticker
Company details
- Status
- Public
- HQ
- San Jose, USA
- Founded
- 1982
- Employees
- 12
- Programs
- 2
- Drugs
- 4
- Patents
- 1
α-lactalbumin vaccine
Phase 1 · mab · Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer
α-lactalbumin vaccine for Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer is a Phase 1 program (mab) at Anixa Biosciences Inc with 1 ClinicalTrials.gov record(s).
Internal code CASE6119
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Anixa Biosciences Inc
- Phase
- Phase 1
- Modality
- mab
- Indication
- Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer
- Status
- active
- Trials
- 1